表紙
市場調査レポート

肝臓病:パイプライン製品の分析

Liver Diseases - Pipeline Review, H2 2013

発行 Global Markets Direct 商品コード 253640
出版日 ページ情報 英文 91 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.75円で換算しております。
Back to Top
肝臓病:パイプライン製品の分析 Liver Diseases - Pipeline Review, H2 2013
出版日: 2013年10月29日 ページ情報: 英文 91 Pages
概要

肝臓病は肝機能の障害により発症する様々な疾病のことを意味します。肝臓は人体の様々な重要機能に関連しており、もし肝臓が病気にかかるか傷つけられれば、これらの機能が低下し、人体に重大な打撃を与えます。また、肝臓は様々な要因(細胞の炎症や胆汁うっ帯、コレステロール蓄積、化学物質による組織損傷など)による打撃を受ける可能性があります。主な兆候として吐き気・嘔吐、継続的な発熱・上腹部痛などが挙げられます。

当レポートでは、世界各国での肝疾患治療法のパイプライン製品の開発状況について分析し、パイプライン製品の最新動向や、治験の各段階にある製品の一覧、主要企業のプロファイル、主な薬剤の概要(製品概要、機能メカニズム、研究開発(R&D)の進展状況)、最新の業界動向などを調査して、その結果を概略以下の構成でお届けします。

イントロダクション

肝臓病の概要

治療薬の開発

  • 肝臓病向けパイプライン製品の概要

各企業で開発中の肝臓病治療薬

大学/研究機関で研究中の肝臓病治療薬

治験の中間段階にある製品

治験の初期段階にある製品

創薬・前臨床段階にある製品

肝臓病治療薬:開発中の製品の一覧(企業別)

肝臓病治療薬:研究中の製品の一覧(大学/研究機関別)

肝臓病治療薬の開発に従事している企業

  • Isis Pharmaceuticals, Inc.
  • Hadasit Medical Research Services & Development Ltd
  • International Stem Cell Corporation
  • Arrowhead Research Corporation
  • PAION AG
  • Alnylam Pharmaceuticals, Inc
  • Proteonomix, Inc.
  • StemCells, Inc.
  • VistaGen Therapeutics , Inc.
  • Jenrin Discovery, Inc.
  • Hutchison MediPharma Limited
  • Ventria Bioscience
  • TetraLogic Pharmaceuticals
  • IC-MedTech, Inc.
  • Jenken Biosciences, Inc
  • MAKScientific, LLC
  • FCB-Pharmicell Co.,Ltd.

肝臓病:治療薬の評価

  • 単剤治療薬の場合
  • 併用治療薬の場合
  • 投与方法別
  • 分子の種類別

薬剤のプロファイル

  • HMPL-011
  • ulimorelin hydrochloride
  • ヒト肝細胞移植
  • ネクロスタチン・プログラム
  • JD-2000シリーズ
  • JD-5000シリーズ
  • JD-6000シリーズ
  • レミマゾラム
  • JKB-121
  • JKB-119
  • HYPER-IL-6
  • UMK-121
  • ISIS-AATRx
  • 肝修復のための細胞治療
  • NKT II細胞のモジュレーター
  • ALN-AAT
  • PV-905
  • Livercellgram
  • 肝細胞由来のヒト単為発生幹細胞
  • 肺病・肝臓病のための化合物
  • RXI-209
  • JD-5006
  • JD-5037
  • AM-6545
  • FFP-104
  • 肝臓病のためのRNA干渉

肝臓病治療薬:最新の薬剤プロファイル

肝臓病治療薬:開発が中止された製品

肝臓病治療薬:開発が休止状態の製品

肝臓病関連製品の開発のマイルストーン

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC4185IDB

Global Markets Direct's, ‘Liver Diseases - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Liver Diseases, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Liver Diseases. Liver Diseases - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Liver Diseases.
  • A review of the Liver Diseases products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Liver Diseases pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Liver Diseases.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Liver Diseases pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Liver Diseases Overview
  • Therapeutics Development
    • An Overview of Pipeline Products for Liver Diseases
  • Liver Diseases Therapeutics under Development by Companies
  • Liver Diseases Therapeutics under Investigation by Universities/Institutes
  • Mid Clinical Stage Products
    • Comparative Analysis
  • Early Clinical Stage Products
    • Comparative Analysis
  • Discovery and Pre-Clinical Stage Products
    • Comparative Analysis
  • Liver Diseases Therapeutics - Products under Development by Companies
  • Liver Diseases Therapeutics - Products under Investigation by Universities/Institutes
  • Companies Involved in Liver Diseases Therapeutics Development
    • Isis Pharmaceuticals, Inc.
    • Hadasit Medical Research Services & Development Ltd
    • International Stem Cell Corporation
    • Arrowhead Research Corporation
    • PAION AG
    • Alnylam Pharmaceuticals, Inc
    • Proteonomix, Inc.
    • StemCells, Inc.
    • VistaGen Therapeutics , Inc.
    • Jenrin Discovery, Inc.
    • Hutchison MediPharma Limited
    • Ventria Bioscience
    • TetraLogic Pharmaceuticals
    • IC-MedTech, Inc.
    • Jenken Biosciences, Inc
    • MAKScientific, LLC
    • FCB-Pharmicell Co.,Ltd.
  • Liver Diseases - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
  • HMPL-011 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ulimorelin hydrochloride - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Human Liver Engrafting Cells - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Necrostatin Program - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • JD-2000 Series - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • JD-5000 Series - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • JD-6000 Series - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • remimazolam - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • JKB-121 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • JKB-119 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • HYPER-IL-6 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • UMK-121 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ISIS-AATRx - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Cell Therapy For Liver Repair - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • NKT II Cell Modulator - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • ALN-AAT - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • PV-905 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Livercellgram - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Human Parthenogenetic Stem Cell Derived Hepatocytes - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Compounds For Lung And Liver Disease - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • RXI-209 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • JD-5006 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • JD-5037 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • AM-6545 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • FFP-104 - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • RNA Interference For Liver Diseases - Drug Profile
    • Product Description
    • Mechanism of Action
    • R&D Progress
  • Liver Diseases Therapeutics - Drug Profile Updates
  • Liver Diseases Therapeutics - Discontinued Products
  • Liver Diseases Therapeutics - Dormant Products
  • Liver Diseases - Product Development Milestones
    • Featured News & Press Releases
      • Sep 23, 2013: Galectin Therapeutics Leadership to Present at Three Upcoming Conferences
      • Sep 05, 2013: Cempra's Solithromycin Demonstrates Safety and Tolerability in Patients With Chronic Liver Disease
      • May 02, 2013: Arena Pharma Withdraws European Marketing Authorization Application For Belviq
      • Mar 06, 2013: Silence Reports Results From Proof-of-concept Studies In Acute Liver Injury
      • Jan 08, 2013: Proteonomix Updates Status Of UMK-121 Testing
      • Nov 20, 2012: Proteonomix Announces Screening Of Patients With End Stage Liver Disease In Clinical Study Of UMK-121
      • Oct 26, 2012: Proteonomix Announces Finalizing ECRF For Clinical Trial Of UMK 121 In Patients With End Stage Liver Disease
      • Oct 12, 2012: StemCells Receives Broad US Patent Covering Expandable Liver Cells
      • Oct 04, 2012: Proteonomix Receives IRB Approval For Clinical Trial Of UMK-121 In Patients With End Stage Liver Disease
      • Sep 12, 2012: Proteonomix Retains Numoda To Provide Clinical Trial Services For Phase I Trial With UMK-121 In End-Stage Liver Disease
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products Under Development for Liver Diseases, H2 2013
  • Products under Development for Liver Diseases - Comparative Analysis, H2 2013
  • Number of Products under Development by Companies, H2 2013
  • Number of Products under Investigation by Universities/Institutes, H2 2013
  • Comparative Analysis by Mid Clinical Stage Development, H2 2013
  • Comparative Analysis by Early Clinical Stage Development, H2 2013
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013
  • Products under Development by Companies, H2 2013
  • Products under Investigation by Universities/Institutes, H2 2013
  • Isis Pharmaceuticals, Inc., H2 2013
  • Hadasit Medical Research Services & Development Ltd, H2 2013
  • International Stem Cell Corporation, H2 2013
  • Arrowhead Research Corporation, H2 2013
  • PAION AG, H2 2013
  • Alnylam Pharmaceuticals, Inc, H2 2013
  • Proteonomix, Inc., H2 2013
  • StemCells, Inc., H2 2013
  • VistaGen Therapeutics , Inc., H2 2013
  • Jenrin Discovery, Inc., H2 2013
  • Hutchison MediPharma Limited, H2 2013
  • Ventria Bioscience, H2 2013
  • TetraLogic Pharmaceuticals, H2 2013
  • IC-MedTech, Inc., H2 2013
  • Jenken Biosciences, Inc, H2 2013
  • MAKScientific, LLC, H2 2013
  • FCB-Pharmicell Co.,Ltd., H2 2013
  • Assessment by Monotherapy Products, H2 2013
  • Assessment by Combination Products, H2 2013
  • Assessment by Stage and Route of Administration, H2 2013
  • Assessment by Stage and Molecule Type, H2 2013
  • Liver Diseases Therapeutics - Drug Profile Updates
  • Liver Diseases Therapeutics - Discontinued Products
  • Liver Diseases Therapeutics - Dormant Products

List of Figures

  • Number of Products under Development for Liver Diseases, H2 2013
  • Products under Development for Liver Diseases - Comparative Analysis, H2 2013
  • Products under Development by Companies, H2 2013
  • Products under Investigation by Universities/Institutes, H2 2013
  • Mid Clinical Stage Products, H2 2013
  • Early Clinical Stage Products, H2 2013
  • Discovery and Pre-Clinical Stage Products, H2 2013
  • Assessment by Monotherapy Products, H2 2013
  • Assessment by Combination Products, H2 2013
  • Assessment by Route of Administration, H2 2013
  • Assessment by Stage and Route of Administration, H2 2013
  • Assessment by Molecule Type, H2 2013
  • Assessment by Stage and Molecule Type, H2 2013
Back to Top